Related references
Note: Only part of the references are listed.Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
Dean J. Kereiakes et al.
AMERICAN HEART JOURNAL (2015)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Christopher P. Cannon et al.
EUROPEAN HEART JOURNAL (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
John J. P. Kastelein et al.
CARDIOVASCULAR DRUGS AND THERAPY (2014)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
Evan A. Stein et al.
EUROPEAN HEART JOURNAL (2014)
Lipoprotein(a) Levels in Familial Hypercholesterolemia An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation
Rodrigo Alonso
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
DECADE IN REVIEW-DYSLIPIDAEMIA Resurgence of targets and compounds to treat dyslipidaemia
John J. P. Kastelein
NATURE REVIEWS CARDIOLOGY (2014)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2011)
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands
A. H. Pijlman et al.
ATHEROSCLEROSIS (2010)
Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal
Roeland Huijgen et al.
PLOS ONE (2010)
Share Paper
